BPTS - Dividend announcements

Success of the placement with professional investors, historical supporters of the Company, for an amount of €1.9M.Strong participation of retail investors via the PrimaryBid platform with an offer allocated to €0.4M[1].Funds raised to finance the Marketing Authorisation Applications of Sarconeos (BIO101) for the treatment of severe forms of COVID-19.PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / May 11, 2023 / Biophytis SA (NasdaqCM:BPTS)(PARIS:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / November 22, 2021 / Biophytis SA (NASDAQ:BPTS)(PARIS:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, announces today that the Company entered into a new loan structure with Kreos Capital.Stanislas Veillet, CEO of BIOPHYTIS, stated: "This transaction allows us to fund the final steps of our COVA phase 2-3 study in COVID-19, mostly for registration under Emergency Use Authorization with the FDA and Conditional Use with the EMA, and the manufact